Published in Facts Views Vis Obgyn on January 01, 2015
Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. Oncoimmunology (2015) 0.83
A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? Facts Views Vis Obgyn (2015) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Regulatory T cells in the control of immune pathology. Nat Immunol (2001) 6.98
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 4.62
Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol (2004) 3.51
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Myeloid-derived suppressor cells in human cancer. Cancer J (2010) 2.36
Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity (2014) 1.69
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother (2006) 1.57
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res (2013) 1.46
Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol (2013) 1.09
The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One (2014) 1.02
Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine (2008) 0.91
Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma. Tumour Biol (2015) 0.87
The role of regulatory T-cells in glioma immunology. Clin Neurol Neurosurg (2014) 0.83
Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer. Tumour Biol (2013) 0.79
Imaging techniques for the pre-surgical diagnosis of adnexal tumours. Best Pract Res Clin Obstet Gynaecol (2014) 0.78